Carbohydrate antigen 125 concentrations across the ejection fraction spectrum in chronic heart failure: The EMPEROR programme

ConclusionAcross the range of EF in patients with chronic HF enrolled in the EMPEROR trials, the majority of whom did not have clinical evidence of congestion, CA-125 concentrations were not significantly associated with congestive signs or symptoms. CA-125 concentrations may predict HF hospitalization/CV death in patients with HFrEF, but not those with HFpEF.Clinical Trial Registration: EMPEROR-Reduced (NCT03057977), EMPEROR-Preserved (NCT03057951).

Source: European Journal of Heart Failure - March 5, 2024 Category: Cardiology Authors: Jo ão Pedro Ferreira, Milton Packer, Naveed Sattar, Javed Butler, Stuart J. Pocock, Stefan D. Anker, Sandra González Maldonado, Marina Panova‐Noeva, Mikhail Sumin, Serge Masson, Faiez Zannad, James L. Januzzi Tags: Research Article Source Type: research